Shares of Atrion Co. (NASDAQ:ATRI) have been given a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation.

Analysts have set a 12-month consensus target price of $300.00 for the company, according to Zacks. Zacks has also given Atrion an industry rank of 147 out of 257 based on the ratings given to related companies.

Separately, BidaskClub raised Atrion from a “hold” rating to a “buy” rating in a report on Friday, September 28th.

Shares of NASDAQ:ATRI traded down $2.90 during midday trading on Monday, hitting $722.11. The company had a trading volume of 9,001 shares, compared to its average volume of 8,048. Atrion has a twelve month low of $516.85 and a twelve month high of $734.90. The stock has a market cap of $1.34 billion, a PE ratio of 38.40 and a beta of 0.56.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 17th. Investors of record on Monday, December 3rd will be issued a $1.35 dividend. The ex-dividend date is Friday, November 30th. This represents a $5.40 annualized dividend and a dividend yield of 0.75%.

Several large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. acquired a new stake in Atrion during the first quarter worth $249,000. UBS Group AG increased its stake in Atrion by 199.2% during the first quarter. UBS Group AG now owns 1,436 shares of the medical instruments supplier’s stock worth $907,000 after acquiring an additional 956 shares during the last quarter. Millennium Management LLC increased its stake in Atrion by 246.8% during the first quarter. Millennium Management LLC now owns 2,719 shares of the medical instruments supplier’s stock worth $1,717,000 after acquiring an additional 1,935 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new stake in Atrion during the first quarter worth $248,000. Finally, Bank of Montreal Can acquired a new stake in Atrion during the second quarter worth $362,000. 63.74% of the stock is owned by hedge funds and other institutional investors.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Read More: How Short Selling Works

Get a free copy of the Zacks research report on Atrion (ATRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.